Maintaining the biologics supply chain in challenging times
As we all adjust to the progressive impact of Covid-19, one consequence has been an increased focus on the biologics supply chain. In such a dynamic and challenging environment, many BioPhorum members are actively engage...
BioPhorum’s revised and improved guidance on single-use change notifications
Changes to critical, complex systems in our regulated environments must be 100% right. This was recognized by the single...
On the road to common solutions in cell and gene therapy
The emerging field of cell and gene therapy (CGT) has only recently started being commercialized and so standard methods...
The essential digital capabilities for CGT manufacturing to succeed at scale
Cell and gene therapies (CGTs) is an emerging, high-growth area, but their manufacture is different from established sma...
BioPhorum expands its technical development reach with innovation hubs
The biopharmaceutical industry is no stranger to making strategic alliances to drive progress throughout all stages of a...
BioPhorum celebrates its 200th membership
Founded in 2008 with one Phorum, Drug Substance, the BioPhorum collaboration has focused on bringing leaders and SMEs to...
BioPhorum’s E&L data review: a momentous step towards better testing
Extractable and leachable (E&L) compounds associated with the use of polymeric single-use systems (SUS) are importan...
Bringing clarity to trace element variations of hydrolysates
Protein hydrolysates are an essential component in cell culture medium formulation during the manufacture of protein the...
How to bring clarity to the testing, validation and release of single-use systems
In the rapidly evolving area of single-use systems (SUSs), the testing of components is critical for process and...
Targeting ‘right first time’ with the new In-silico Strategies Workstream
In-silico modeling is an exciting, new area for many biomanufacturers as it creates the opportunity to reduce wasted exp...
How industry is using technology during the COVID-19 pandemic
The use of technology in its many forms was a recurring theme in BioPhorum’s recent COVID-19 Workforce Protection Surv...
New risk-based deviation management system can save members an average of 22,200 hours per site
Under a traditional deviation management system (DMS), all events are considered equal and usually require a 30-day clos...
How to assess EHS risks for commercial-scale CGT manufacture
The rapidly expanding field of cell and gene therapies (CGT) has the potential to revolutionize curative treatments. How...
